Mesa Laboratories, Inc. (NASDAQ:MLAB) has been given an average broker rating score of 1.00 (Strong Buy) from the one analysts that provide coverage for the stock, Zacks Investment Research reports. One research analyst has rated the stock with a strong buy rating. Mesa Laboratories’ rating score has improved by 50% in the last three months as a result of various analysts’ upgrades and downgrades.

Brokers have set a 1-year consensus price target of $190.00 for the company and are predicting that the company will post $0.57 EPS for the current quarter, according to Zacks. Zacks has also assigned Mesa Laboratories an industry rank of 187 out of 265 based on the ratings given to its competitors.

A number of brokerages have recently issued reports on MLAB. TheStreet downgraded shares of Mesa Laboratories from a “b” rating to a “c+” rating in a report on Monday, July 31st. Zacks Investment Research upgraded shares of Mesa Laboratories from a “hold” rating to a “buy” rating and set a $159.00 price target for the company in a report on Tuesday, June 13th. Finally, BidaskClub cut shares of Mesa Laboratories from a “sell” rating to a “strong sell” rating in a research note on Saturday, August 12th.

In related news, Director H Stuart Campbell sold 608 shares of the firm’s stock in a transaction that occurred on Friday, August 11th. The shares were sold at an average price of $134.08, for a total value of $81,520.64. Following the sale, the director now directly owns 45,368 shares of the company’s stock, valued at $6,082,941.44. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Glenn E. Adriance sold 4,000 shares of the firm’s stock in a transaction that occurred on Friday, June 9th. The stock was sold at an average price of $148.98, for a total transaction of $595,920.00. Following the completion of the sale, the insider now directly owns 10,000 shares in the company, valued at $1,489,800. The disclosure for this sale can be found here. Over the last three months, insiders sold 24,760 shares of company stock worth $3,469,708. 17.00% of the stock is owned by corporate insiders.

Several large investors have recently added to or reduced their stakes in the company. Voya Investment Management LLC bought a new stake in Mesa Laboratories during the second quarter valued at about $221,000. Strs Ohio boosted its stake in Mesa Laboratories by 5.6% in the second quarter. Strs Ohio now owns 1,900 shares of the medical instruments supplier’s stock valued at $272,000 after buying an additional 100 shares in the last quarter. BT Investment Management Ltd bought a new stake in Mesa Laboratories during the second quarter valued at about $277,000. Spark Investment Management LLC bought a new stake in Mesa Laboratories during the second quarter valued at about $300,000. Finally, The Manufacturers Life Insurance Company boosted its stake in Mesa Laboratories by 7.1% in the second quarter. The Manufacturers Life Insurance Company now owns 2,564 shares of the medical instruments supplier’s stock valued at $367,000 after buying an additional 169 shares in the last quarter. 67.21% of the stock is currently owned by institutional investors and hedge funds.

Shares of Mesa Laboratories (MLAB) traded up 5.01% on Monday, reaching $135.08. 33,818 shares of the company traded hands. The stock has a market capitalization of $507.63 million, a price-to-earnings ratio of 48.55 and a beta of 0.46. The company has a 50-day moving average of $140.75 and a 200-day moving average of $136.69. Mesa Laboratories has a 1-year low of $103.51 and a 1-year high of $169.80.

Mesa Laboratories (NASDAQ:MLAB) last announced its quarterly earnings results on Monday, July 31st. The medical instruments supplier reported $0.39 earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of $0.56 by $0.17. The company had revenue of $22.67 million during the quarter, compared to analysts’ expectations of $22.90 million. Mesa Laboratories had a net margin of 11.31% and a return on equity of 16.58%. Analysts anticipate that Mesa Laboratories will post $2.72 earnings per share for the current fiscal year.

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, September 15th. Investors of record on Thursday, August 31st will be paid a $0.16 dividend. The ex-dividend date of this dividend is Tuesday, August 29th. This represents a $0.64 dividend on an annualized basis and a yield of 0.47%. Mesa Laboratories’s payout ratio is 22.94%.

COPYRIGHT VIOLATION WARNING: “Zacks: Mesa Laboratories, Inc. (MLAB) Given Average Rating of “” by Brokerages” was first published by American Banking News and is owned by of American Banking News. If you are accessing this article on another publication, it was copied illegally and republished in violation of international trademark and copyright law. The original version of this article can be read at https://www.americanbankingnews.com/2017/08/28/zacks-mesa-laboratories-inc-mlab-given-average-rating-of-by-brokerages.html.

About Mesa Laboratories

Mesa Laboratories, Inc is focused primarily on quality control products and services. The Company operates through four segments: Instruments, Continuous Monitoring, Biological Indicators and Cold Chain. The Instruments Division designs, manufactures and markets quality control instruments and disposable products.

Get a free copy of the Zacks research report on Mesa Laboratories (MLAB)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Mesa Laboratories Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mesa Laboratories Inc. and related companies with MarketBeat.com's FREE daily email newsletter.